Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children

Archive ouverte

Orenti, Annalisa | Pranke, Iwona | Faucon, Caroline | Varilh, Jessica | Hatton, Aurelie | Golec, Anita | Dehillotte, Clemence | Durieu, Isabelle | Reix, Philippe | Burgel, Pierre-Régis | Grenet, Dominique | Tasset, Céline | Gachelin, Elsa | Perisson, Caroline | Lepissier, Agathe | Dreano, Elise | Tondelier, Danielle | Chevalier, Benoit | Weiss, Laurence | Kiefer, Sébastien | Laurans, Muriel | Chiron, Raphael | Lemonnier, Lydie | Marguet, Christophe | Jung, Andreas | Edelman, Aleksander | Kerem, Bat-Sheva | Girodon, Emmanuelle | Taulan, Magali | Hinzpeter, Alexandre | Kerem, Eitan | Naehrlich, Lutz | Sermet-Gaudelus, Isabelle

Edité par CCSD ; Elsevier -

International audience. Rationale: Limited information is available on the clinical status of people with Cystic Fibrosis (pwCF) carrying 2 nonsense mutations (PTC/PTC). The main objective of this study was to compare disease severity between pwCF PTC/PTC, compound heterozygous for F508del and PTC (F508del/PTC) and homozygous for F508del (F508del+/+).Methods: Based on the European CF Society Patient Registry clinical data of pwCF living in high and middle income European and neighboring countries, PTC/PTC (n = 657) were compared with F508del+/+ (n = 21,317) and F508del/PTC(n = 4254).CFTR mRNA and protein activity levels were assessed in primary human nasal epithelial (HNE) cells sampled from 22 PTC/PTC pwCF.Main results: As compared to F508del+/+ pwCF; both PTC/PTC and F508del/PTC pwCF exhibited a significantly faster rate of decline in Forced Expiratory Volume in 1 s (FEV1) from 7 years (-1.33 for F508del +/+, -1.59 for F508del/PTC; -1.65 for PTC/PTC, p < 0.001) until respectively 30 years (-1.05 for F508del +/+, -1.23 for PTC/PTC, p = 0.048) and 27 years (-1.12 for F508del +/+, -1.26 for F508del/PTC, p = 0.034). This resulted in lower FEV1 values in adulthood. Mortality of pediatric pwCF with one or two PTC alleles was significantly higher than their F508del homozygous pairs. Infection with Pseudomonas aeruginosa was more frequent in PTC/PTC versus F508del+/+ and F508del/PTC pwCF. CFTR activity in PTC/PTC pwCF's HNE cells ranged between 0% to 3% of the wild-type level.Conclusions: Nonsense mutations decrease the survival and accelerate the course of respiratory disease in children and adolescents with Cystic Fibrosis

Suggestions

Du même auteur

Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription

Archive ouverte | Dreano, Elise | CCSD

International audience. Background Around 20% of people with cystic fibrosis (pwCF) do not have access to the triple combination elexacaftor/tezacaftor/ivacaftor (ETI) in Europe because they do not carry the F508del...

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Archive ouverte | Burgel, Pierre-Régis | CCSD

International audience. Background Elexacaftor-tezacaftor-ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant. Additionally, it is approved by the US Food and...

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Archive ouverte | Burgel, Pierre-Régis | CCSD

International audience

Chargement des enrichissements...